Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)
Carnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment wit...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/14/2/343 |
| _version_ | 1797491369659334656 |
|---|---|
| author | Shota Matsufuji Tetsuo Shoji Suhye Lee Masao Yamaguchi Mari Nishimura Yoshihiro Tsujimoto Shinya Nakatani Tomoaki Morioka Katsuhito Mori Masanori Emoto |
| author_facet | Shota Matsufuji Tetsuo Shoji Suhye Lee Masao Yamaguchi Mari Nishimura Yoshihiro Tsujimoto Shinya Nakatani Tomoaki Morioka Katsuhito Mori Masanori Emoto |
| author_sort | Shota Matsufuji |
| collection | DOAJ |
| description | Carnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment with levocarnitine with the change in knee extensor strength (KES) in hemodialysis patients. Eligible patients were selected from the participants enrolled in a prospective cohort study for whom muscle strength was measured annually. We identified 104 eligible patients for this analysis. During the one-year period between 2014 to 2015, 67 patients were treated with intravenous levocarnitine (1000 mg per shot, thrice weekly), whereas 37 patients were not. The change in KES was significantly higher (<i>p</i> = 0.01) in the carnitine group [0.02 (0.01–0.04) kgf/kg] as compared to the non-carnitine group [−0.02 (−0.04 to 0.01) kgf/kg]. Multivariable-adjusted regression analysis showed the positive association between the change in KES and the treatment with levocarnitine remained significant after adjustment for the baseline KES and other potential confounders. Thus, treatment with intravenous levocarnitine was independently and positively associated with the change in KES among hemodialysis patients. Further clinical trials are needed to provide more solid evidence. |
| first_indexed | 2024-03-10T00:47:28Z |
| format | Article |
| id | doaj.art-cf2ea5e9d2614e619d350e372954173d |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T00:47:28Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-cf2ea5e9d2614e619d350e372954173d2023-11-23T14:57:57ZengMDPI AGNutrients2072-66432022-01-0114234310.3390/nu14020343Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)Shota Matsufuji0Tetsuo Shoji1Suhye Lee2Masao Yamaguchi3Mari Nishimura4Yoshihiro Tsujimoto5Shinya Nakatani6Tomoaki Morioka7Katsuhito Mori8Masanori Emoto9Division of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, JapanDepartment of Vascular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, JapanDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, JapanDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, JapanDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, JapanDivision of Internal Medicine, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, JapanDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, JapanDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, JapanDepartment of Nephrology, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, JapanVascular Science Center for Translational Research, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, JapanCarnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment with levocarnitine with the change in knee extensor strength (KES) in hemodialysis patients. Eligible patients were selected from the participants enrolled in a prospective cohort study for whom muscle strength was measured annually. We identified 104 eligible patients for this analysis. During the one-year period between 2014 to 2015, 67 patients were treated with intravenous levocarnitine (1000 mg per shot, thrice weekly), whereas 37 patients were not. The change in KES was significantly higher (<i>p</i> = 0.01) in the carnitine group [0.02 (0.01–0.04) kgf/kg] as compared to the non-carnitine group [−0.02 (−0.04 to 0.01) kgf/kg]. Multivariable-adjusted regression analysis showed the positive association between the change in KES and the treatment with levocarnitine remained significant after adjustment for the baseline KES and other potential confounders. Thus, treatment with intravenous levocarnitine was independently and positively associated with the change in KES among hemodialysis patients. Further clinical trials are needed to provide more solid evidence.https://www.mdpi.com/2072-6643/14/2/343muscle strengthhemodialysiscarnitine deficiencysarcopeniafrailty |
| spellingShingle | Shota Matsufuji Tetsuo Shoji Suhye Lee Masao Yamaguchi Mari Nishimura Yoshihiro Tsujimoto Shinya Nakatani Tomoaki Morioka Katsuhito Mori Masanori Emoto Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) Nutrients muscle strength hemodialysis carnitine deficiency sarcopenia frailty |
| title | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
| title_full | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
| title_fullStr | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
| title_full_unstemmed | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
| title_short | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
| title_sort | association between levocarnitine treatment and the change in knee extensor strength in patients undergoing hemodialysis a post hoc analysis of the osaka dialysis complication study odcs |
| topic | muscle strength hemodialysis carnitine deficiency sarcopenia frailty |
| url | https://www.mdpi.com/2072-6643/14/2/343 |
| work_keys_str_mv | AT shotamatsufuji associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT tetsuoshoji associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT suhyelee associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT masaoyamaguchi associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT marinishimura associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT yoshihirotsujimoto associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT shinyanakatani associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT tomoakimorioka associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT katsuhitomori associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs AT masanoriemoto associationbetweenlevocarnitinetreatmentandthechangeinkneeextensorstrengthinpatientsundergoinghemodialysisaposthocanalysisoftheosakadialysiscomplicationstudyodcs |